Table 1. Patient characteristics at baseline (n=54).
| Characteristic | Value | ||
|---|---|---|---|
| Age (yr) | 65 (38–88) | ||
| ECOG performance status | |||
| 0 | 35 (64.8) | ||
| 1 | 19 (35.2) | ||
| Tumor grade | |||
| Grade 1 (well differentiated) | 4 (7.4) | ||
| Grade 2 (moderately differentiated) | 5 (9.2) | ||
| Grade 3 (poorly or undifferentiated) | 40 (74.1) | ||
| Unknown | 4 (7.4) | ||
| Missing | 1 (1.9) | ||
| Prior chemotherapy | 54 (100.0) | ||
| Lines of prior chemotherapy | |||
| 1 | 50 (92.6) | ||
| ≥2 | 4 (7.4) | ||
| Method of response measurement | |||
| RECIST v1.1 | 17 (31.5) | ||
| CA125 by GCIG criteria | 37 (68.5) | ||
| Histology | |||
| High grade serous | 40 (74.1) | ||
| Low grade serous | 5 (9.3) | ||
| Serous carcinoma, unknown grade | 4 (7.4) | ||
| Endometrioid | 4 (7.4) | ||
| Clear cell carcinoma | 1 (1.9) | ||
| Patients with % of tumor stained ER-positive | 52* | ||
| <50% | 8 (15.4) | ||
| 50%–89% | 14 (26.9) | ||
| 90%–100% | 30 (57.7) | ||
| ER/PR nuclear staining | 30† | ||
| ER staining (intensity) | |||
| Negative | 1 (3.3) | ||
| Weak (1+) | 3 (10.0) | ||
| Moderate (1.5–2+) | 18 (60.0) | ||
| Strong (2.5–3+) | 8 (26.7) | ||
| ER histoscores | |||
| 0–100 | 9 (30.0) | ||
| 101–200 | 13 (43.3) | ||
| 201–300 | 8 (26.7) | ||
| PR staining (intensity) | |||
| Negative | 12 (40.0) | ||
| Weak (1+) | 12 (40.0) | ||
| Moderate (1.5–2+) | 4 (13.3) | ||
| Strong (2.5–3+) | 2 (6.7) | ||
| PR histoscores | |||
| 0–100 | 28 (93.3) | ||
| 101–200 | 0 | ||
| 201–300 | 2 (6.7) | ||
Values shown are number (%) or mean (range).
CA125, cancer antigen 125; ECOG, Eastern Cooperative Oncology Group; ER, estrogen receptor; GCIG, Gynecologic Cancer InterGroup; PR, progesterone receptor; RECIST, Response Evaluation Criteria in Solid Tumors.
*Fifty-two patients with tissue available for ER confirmation; †ER/PR intensity and histoscores, on tissue microarray, were available in 30 patients.